Cargando…
Combination therapy (toripalimab and lenvatinib)-associated toxic epidermal necrolysis in a patient with metastatic liver cancer: A case report
BACKGROUND: Both programmed cell death-1 (PD-1) inhibitors and lenvatinib, which have a synergistic effect, are promising drugs for tumor treatment. It is generally believed that combination therapy with a PD-1 inhibitor and lenvatinib is safe and effective. However, we report a case of toxic epider...
Autores principales: | Huang, Kai-Kai, Han, Shan-Shan, He, Li-Ya, Yang, Lin-Lin, Liang, Bao-Ying, Zhen, Qing-Yu, Zhu, Zi-Bo, Zhang, Cai-Yun, Li, Hong-Yi, Lin, Ying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9048562/ https://www.ncbi.nlm.nih.gov/pubmed/35611193 http://dx.doi.org/10.12998/wjcc.v10.i11.3478 |
Ejemplares similares
-
A case of toxic epidermal necrolysis associated with lenvatinib and
sintilimab therapy for intrahepatic cholangiocarcinoma
por: Gong, Yinhua, et al.
Publicado: (2023) -
Toxic Epidermal Necrolysis
por: Khalifian, Saami, et al.
Publicado: (2014) -
Toxic epidermal necrolysis
por: Hoetzenecker, Wolfram, et al.
Publicado: (2016) -
Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma
por: He, Min-Ke, et al.
Publicado: (2021) -
Toxic Epidermal Necrolysis Induced by Sintilimab: A Case Report
por: Lye, Ya-lei, et al.
Publicado: (2023)